GABA(A) receptor alpha4 subunit suppression prevents withdrawal properties of an endogenous steroid.
The hormone progesterone is readily converted to 3alpha-OH-5alpha-pregnan-20-one (3alpha,5alpha-THP) in the brains of males and females. In the brain, 3alpha,5alpha-THP acts like a sedative, decreasing anxiety and reducing seizure activity, by enhancing the function of GABA (gamma-aminobutyric acid), the brain's major inhibitory neurotransmitter. Symptoms of premenstrual syndrome (PMS), such as anxiety and seizure susceptibility, are associated with sharp declines in circulating levels of progesterone and, consequently, of levels of 3alpha,5alpha-THP in the brain. Abrupt discontinuation of use of sedatives such as benzodiazepines and ethanol can also produce PMS-like withdrawal symptoms. Here we report a progesterone-withdrawal paradigm, designed to mimic PMS and post-partum syndrome in a rat model. In this model, withdrawal of progesterone leads to increased seizure susceptibility and insensitivity to benzodiazepine sedatives through an effect on gene transcription. Specifically, this effect was due to reduced levels of 3alpha,5alpha-THP which enhance transcription of the gene encoding the alpha4 subunit of the GABA(A) receptor. We also find that increased susceptibility to seizure after progesferone withdrawal is due to a sixfold decrease in the decay time for GABA currents and consequent decreased inhibitory function. Blockade of the alpha4 gene transcript prevents these withdrawal properties. PMS symptoms may therefore be attributable, in part, to alterations in expression of GABA(A) receptor subunits as a result of progesterone withdrawal.
Smith
S S
SS
Department of Neurobiology and Anatomy, Allegheny University of the Health Sciences, Philadelphia, Pennsylvania 19129, USA. smiths@auhs.edu
Gong
Q H
QH
Hsu
F C
FC
Markowitz
R S
RS
ffrench-Mullen
J M
JM
Li
X
X
D000818:Animals; D014151:Anti-Anxiety Agents / Q000494:pharmacology*; D001386:Azides / Q000494:pharmacology; D001569:Benzodiazepines / Q000494:pharmacology; D002243:Carbolines / Q000494:pharmacology; D005260:Female; D006624:Hippocampus / Q000378:metabolism; D007213:Indomethacin / Q000494:pharmacology; D008140:Lorazepam / Q000494:pharmacology; D016376:Oligonucleotides, Antisense / Q000494:pharmacology; D018408:Patch-Clamp Techniques; D011280:Pregnanolone / Q000008:administration & dosage / Q000378:metabolism* / Q000494:pharmacology; D011293:Premenstrual Syndrome / Q000209:etiology / Q000378:metabolism*; D011374:Progesterone / Q000008:administration & dosage / Q000378:metabolism* / Q000494:pharmacology; D017966:Pyramidal Cells / Q000187:drug effects / Q000378:metabolism; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D051381:Rats; D011963:Receptors, GABA-A / Q000235:genetics / Q000378:metabolism*; D014158:Transcription, Genetic; D005680:gamma-Aminobutyric Acid / Q000378:metabolism
D014151:Anti-Anxiety Agents; D001386:Azides; D002243:Carbolines; D016376:Oligonucleotides, Antisense; D012333:RNA, Messenger; D011963:Receptors, GABA-A; D001569:Benzodiazepines; D011374:Progesterone; D005680:gamma-Aminobutyric Acid; C035874:FG 7142; C042957:Ro 15-4513; D011280:Pregnanolone; D008140:Lorazepam; D007213:Indomethacin